Roundhill Russell 2000 0DTE Covered Call Strat ETF vs 22nd Century Group Inc — how do they compare? Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $28.4, while 22nd Century Group Inc trades at $4.15 (market cap $1.56M). The key difference: Roundhill Russell 2000 0DTE Covered Call Strat ETF is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals.
| RDTE | XXII | |
|---|---|---|
Sector | Income / Options Overlay | Technology |
52-Week High | $34.72 | $999.00 |
52-Week Low | $26.40 | $3.90 |
Market Cap | — | $1.56M |
Enterprise Value | — | -$6.67M |
Signals from Pluang's Aura AI — not financial advice
RDTE stock trades at $28.57, down 0.38% on the day, with a bearish technical signal from moving averages and neutral oscillators. The company has announced multiple small dividends for 2026, but key valuation and profitability ratios are unavailable. Recent news highlights concerns about the fund's strategy and capital erosion risks.
The outlook is cautious due to structural risks in the covered call strategy capping upside and exposing downside, as noted by Seeking Alpha. Investment opportunity hinges on income from dividends, but risks of NAV deterioration and negative media sentiment present significant headwinds for shareholders.
No Aura AI signal available yet.
Trailing returns across standard periods
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →